ECP 2026: Epidermal Biomarker Resolves Tricky Skin Lesions - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ECP 2026: Epidermal Biomarker Resolves Tricky Skin Lesions

Study investigates the diagnostic utility of epidermal CD271 IHC expression in challenging melanocytic lesions

  • September 18, 2026

  • 3 min

Share

Clinical Report: Epidermal Biomarker Resolves Tricky Skin Lesions

Overview

A study presented at ECP 2026 demonstrated that epidermal CD271 expression significantly outperformed traditional markers Ki67 and PRAME in diagnosing challenging melanocytic lesions.

Background

Diagnosing melanocytic lesions is a complex task that often challenges even experienced pathologists. Traditional immunohistochemical markers like Ki67 and PRAME are useful but have limitations in specificity and sensitivity.

Data Highlights

MarkerROC Curve
CD2710.93
PRAME0.84
Ki670.83

Key Findings

  • CD271 expression in basal keratinocytes was consistent in benign nevi but disrupted in melanomas.
  • CD271 outperformed Ki67 and PRAME in diagnostic performance with a ROC curve of 0.93.
  • The study involved 156 challenging melanocytic lesions assessed through immunohistochemical staining.
  • Statistically significant differences were observed across benign, intermediate, and malignant lesion classes.

Clinical Implications

The use of CD271 as a biomarker may enhance the diagnostic process for challenging melanocytic lesions.

Conclusion

The study highlights the potential of CD271 in improving the diagnostic accuracy of melanocytic lesions.

Related Resources & Content

  1. Patricia Switten Nielsen, ECP 2026 -- Epidermal Biomarker Resolves Tricky Skin Lesions
  2. the pathologist — (AI) Skin in the Game
  3. MDSpire News — Nonblistering Papules: Genetic Mystery Cracked
  4. MDSpire News — New Biomarkers Reveal Topical Treatment Effects
  5. the pathologist — Pathology: What’s In the News?
  6. AI Skin in the Game
  7. Nonblistering Papules: Genetic Mystery Cracked
  8. New Biomarkers Reveal Topical Treatment Effects
  9. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
  10. Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma - PMC
  11. NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation - PMC

Original Source(s)

ECP 2026: Epidermal Biomarker Resolves Tricky Skin Lesions

  • September 18, 2026

Related Content

Can Technology Make Pathology More Human? Part 3

Our panel discusses AI accountability, user trust, and desirable outcomes

Mild metabolic profile may mask MASLD risk

Five reproducible MASLD subtypes showed distinct genetic profiles and patterns of metabolic comorbidity and disease progression.

Amyloid Seeds Emerge as Blood Biomarker

Plasma aggregation activity separates Alzheimer’s disease from non-Alzheimer’s dementias

  • September 8, 2026

  • 3 min